While some clinicians originally raised the possibility that ACE inhibitors (ACEI) or angiotensin receptor blockers (ARBs), used as a treatment for hypertension in COVID-19 patients could increase the severity and mortality of COVID-19 based on the fact that ACE inhibitors and ARBs increase ACE 2 expression [18], there is no evidence supporting worse outcomes with the use of these drugs. The gene discussed is ACE; the disease is hypertensive disorder.